SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,312,948 | -31.3% | 297,035 | -0.9% | 2.89% | -32.0% |
| Q2 2023 | $6,275,672 | -10.0% | 299,841 | -9.1% | 4.25% | -17.2% |
| Q1 2023 | $6,969,600 | -15.6% | 330,000 | +1.7% | 5.13% | +1.0% |
| Q4 2022 | $8,261,426 | +5.9% | 324,614 | 0.0% | 5.08% | +51.4% |
| Q3 2022 | $7,800,000 | +97.8% | 324,614 | +58.3% | 3.36% | +52.9% |
| Q2 2022 | $3,944,000 | +10.1% | 205,003 | -0.5% | 2.20% | +31.2% |
| Q1 2022 | $3,582,000 | -20.6% | 206,126 | 0.0% | 1.67% | -11.8% |
| Q4 2021 | $4,512,000 | +14.5% | 206,126 | 0.0% | 1.90% | +36.5% |
| Q3 2021 | $3,939,000 | +11.3% | 206,126 | 0.0% | 1.39% | -1.7% |
| Q2 2021 | $3,539,000 | -38.0% | 206,126 | -19.2% | 1.41% | -31.3% |
| Q1 2021 | $5,706,000 | -44.9% | 255,180 | -45.2% | 2.06% | -27.0% |
| Q4 2020 | $10,353,000 | +191.4% | 465,500 | +93.4% | 2.82% | +191.9% |
| Q3 2020 | $3,553,000 | -0.4% | 240,744 | 0.0% | 0.96% | -6.4% |
| Q2 2020 | $3,568,000 | – | 240,744 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |